Cyrus B. Ravandi
Boston, MA · Advising & speaking

I turn scientific ambition into AI that earns its place.

Data & AI product strategy leader in biopharma research and translational science. Twelve years of computational work, five of them building AI capability inside R&D — where the measure of a model is not adoption, but a better decision made sooner.

Discover with Purpose.

01

Selected work

Enterprise strategy 2024 — today

Scientific intelligence, measured by decisions

Defined the enterprise product strategy that moved R&D AI evaluation off usage dashboards and onto research impact, decision quality, and value. The decision framework it produced now guides AI investment, platform, and vendor priorities.

Product visionRoadmapAI governanceValue measurement
Translational AI 2023 — 2026

Rare disease borrows from common biology

Built a translational strategy that used shared mechanism to work around sparse rare-disease data, integrating biological, clinical, and real-world evidence. Applied across seven assets to prioritize repurposing and indication expansion.

Dis2VecKnowledge graphsIndication strategy
Evaluation 2023 — today

Benchmark-first, or it does not ship

Grounded model and vendor assessment in biological evidence and real clinical-trial decisions rather than leaderboard scores — five vendors evaluated, two academic partnerships established, including Orphanet and the European Reference Networks.

BenchmarkingVendor strategyGeneralizability
02

Track record

12+
Years across computational science, data, and AI
3
AI products delivered and adopted in R&D
20
Peer-reviewed publications, 500+ citations
30k
Rare-disease experts reached via Orphanet & ERN

Published in

Nature CommunicationsNature FoodPNASBioinformatics
03

Publications

Twenty peer-reviewed papers and preprints on generalizability, negative sampling, disease representation, and measurement in biological machine learning — 500+ citations. Recent work:

  1. 2026

    Ravandi, C. B., et al. (2026). Clinical trial and ontology-derived positive and negative benchmark datasets for drug repurposing across rare diseases. Scientific Data (in review).

  2. 2026

    Ravandi, C. B., et al. (2026). A mechanistic disease representation framework for therapeutic knowledge transfer across rare and common conditions. bioRxiv, 2024.11.19.624381.

  3. 2025

    Ravandi, C. B., et al. (2025). Topology-driven negative sampling enhances generalizability in protein–protein interaction prediction. Bioinformatics, btaf148.

  4. 2025

    Chatterjee, A., Ikica, B., Ravandi, C. B., et al. (2025). Transfer learning for temporal link prediction. International Joint Conference on Neural Networks (IJCNN), 1–8.

  5. 2025

    Ravandi, C. B., et al. (2025). Prevalence of processed foods in major US grocery stores. Nature Food.

    Nature Food rdcu.be/d55mU
  6. 2024

    Nabizadeh, M., Nasirian, F., … Ravandi, C. B., et al. (2024). Network physics of attractive colloidal gels: Resilience, rigidity, and phase diagram. Proceedings of the National Academy of Sciences.

  7. 2023

    Menichetti, G., Ravandi, C. B., et al. (2023). Machine learning prediction of the degree of food processing. Nature Communications, 14, 2312.

  8. 2019

    Ravandi, C. B., et al. (2019). Impact of plate size on food waste: Agent-based simulation of food consumption. Resources, Conservation and Recycling.

  9. 2018

    Ravandi, C. B., et al. (2018). A self-organized resource provisioning for cloud block storage. Future Generation Computer Systems.

Full list on Google Scholar.

If you are deciding where AI belongs in your research organization, I am glad to think it through with you.

Advisory, board conversations, and talks. Boston-based, working globally.